CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma

BMC Clinical Pathology

Volumn 9, Issue 1, 2009, Pages

  Williams, Ariel A ^a   Higgins, John P T ^b   Zhao, Hongjuan ^b   Ljunberg, Börje ^c   Brooks, James D ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD9 ANTIGEN; VIMENTIN;

ARTICLE; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; CONTROLLED STUDY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

EID: 72849133726     PISSN: 14726890     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-9-9     Document Type: Article

References (65)

1. SEER Cancer Statistics Review, 1975-2005. LAG Ries D Melbert M Krapcho DG Stinchcomb N Howlader MJ Horner A Mariotto BA Miller EJ Feuer SF Altekruse Eds, et al. Bethseda, MD: National Cancer Institute 2008
2. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. JN Eble G Sauter JI Epstein IA Sesterhenn Eds, Lyons: IARC Press 2004
3. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. MB Amin P Tamboli J Javidan H Stricker M de-Peralta Venturina A Deshpande M Menon, Am J Surg Pathol 2002 26 281 291
4. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy. DS Dimarco CM Lohse H Zincke JC Cheville ML Blute, Urology 2004 64 462 467
5. Sorafenib in advanced clear-cell renal-cell carcinoma. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai, et al. N Engl J Med 2007 356 125 134
6. Prognostic significance of the Heidelberg classification of renal cell carcinoma. B Ljungberg FI Alamdari R Stenling G Roos, Eur Urol 1999 36 565 569 (Pubitemid 29516286)
7. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim, et al. N Engl J Med 2007 356 115 124 (Pubitemid 46089672)
8. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. MP Upton RA Parker A Youmans DF McDermott MB Atkins, J Immunother 2005 28 488 495
9. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. TK Choueiri A Plantade P Elson S Negrier A Ravaud S Oudard M Zhou BI Rini RM Bukowski B Escudier, J Clin Oncol 2008 26 127 131
10. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. D Strumberg, J Clin Oncol 2008 26 3469 3471
11. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. A Volpe K Mattar A Finelli JR Kachura AJ Evans WR Geddie MA Jewett, J Urol 2008 180 2333 2337
12. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. BA Shannon RJ Cohen H de Bruto RJ Davies, J Urol 2008 180 1257 1261
13. Renal mass biopsy - a renaissance? BR Lane MK Samplaski BR Herts M Zhou AC Novick SC Campbell, J Urol 2008 179 20 27
14. Diagnostic yield of renal biopsy immediately prior to laparoscopic radiofrequency ablation: a multicenter study. CC Kyle MS Wingo RI Carey RJ Leveillee VG Bird, J Endourol 2008 22 2291 2293
15. Percutaneous and laparoscopic cryoablation of small renal masses. DS Finley S Beck G Box W Chu L Deane DJ Vajgrt EM McDougall RV Clayman, J Urol 2008 180 492 498
16. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. M Takahashi XJ Yang J Sugimura J Backdahl M Tretiakova CN Qian SG Gray R Knapp J Anema R Kahnoski, et al. Oncogene 2003 22 6810 6818
17. Molecular classification of renal tumors by gene expression profiling. AN Schuetz Q Yin-Goen MB Amin CS Moreno C Cohen CD Hornsby WL Yang JA Petros MM Issa JG Pattaras, et al. J Mol Diagn 2005 7 206 218
18. An immunohistochemical approach to the differential diagnosis of renal tumors. BF Skinnider MB Amin, Semin Diagn Pathol 2005 22 51 68
19. Gene expression profiling predicts survival in conventional renal cell carcinoma. H Zhao B Ljungberg K Grankvist T Rasmuson R Tibshirani JD Brooks, PLoS Med 2006 3 13
20. Gene Expression Omnibus (GSE3538). http://www.ncbi.nlm.nih.gov/sites/ entrez
21. Significance analysis of microarrays applied to the ionizing radiation response. VG Tusher R Tibshirani G Chu, Proc Natl Acad Sci USA 2001 98 5116 5121
22. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. CL Liu W Prapong Y Natkunam A Alizadeh K Montgomery CB Gilks M van de Rijn, Am J Pathol 2002 161 1557 1565
23. Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. NA Abrahams GT MacLennan JD Khoury AH Ormsby P Tamboli C Doglioni B Schumacher SK Tickoo, Histopathology 2004 45 593 602
24. Colloidal iron staining in renal epithelial neoplasms, including chromophobe renal cell carcinoma: emphasis on technique and patterns of staining. SK Tickoo MB Amin RJ Zarbo, Am J Surg Pathol 1998 22 419 424
25. Cytokeratins 7 and 20 immunoreactivity in chromophobe renal cell carcinomas and renal oncocytomas. SL Wu P Kothari TM Wheeler T Reese JH Connelly, Mod Pathol 2002 15 712 717
26. Antimitochondrial antibody (113-1) in the differential diagnosis of granular renal cell tumors. SK Tickoo MB Amin MD Linden MW Lee RJ Zarbo, Am J Surg Pathol 1997 21 922 930
27. Renal oncocytoma and chromophobe renal cell carcinoma. A comparison of colloidal iron staining and electron microscopy. BF Skinnider EC Jones, Am J Clin Pathol 1999 111 796 803
28. Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. ME Mathers AM Pollock C Marsh M O'Donnell, Histopathology 2002 40 563 567
29. The natural history of incidentally detected small renal masses. A Volpe T Panzarella RA Rendon MA Haider FI Kondylis MA Jewett, Cancer 2004 100 738 745
30. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. MJ Wehle DD Thiel SP Petrou PR Young I Frank N Karsteadt, Urology 2004 64 49 52
31. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. J Lapointe C Li JP Higgins M van de Rijn E Bair K Montgomery M Ferrari L Egevad W Rayford U Bergerheim, et al. Proc Natl Acad Sci USA 2004 101 811 816
32. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. JP Higgins G Kaygusuz L Wang K Montgomery V Mason SX Zhu RJ Marinelli JC Presti Jr M van de Rijn JD Brooks, Am J Surg Pathol 2007 31 673 680
33. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. J Luo S Zha WR Gage TA Dunn JL Hicks CJ Bennett CM Ewing EA Platz S Ferdinandusse RJ Wanders, et al. Cancer Res 2002 62 2220 2226
34. Expression of intermediate filament proteins in subtypes of renal cell carcinomas and in renal oncocytomas. Distinction of two classes of renal cell tumors. S Pitz R Moll S Storkel W Thoenes, Lab Invest 1987 56 642 653
35. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. L Liu J Qian H Singh I Meiers X Zhou DG Bostwick, Arch Pathol Lab Med 2007 131 1290 1297
36. The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma. JD Khoury NA Abrahams HS Levin GT MacLennan, Ann Diagn Pathol 2002 6 154 158
37. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. AK Avery J Beckstead AA Renshaw CL Corless, Am J Surg Pathol 2000 24 203 210
38. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. AN Young MB Amin CS Moreno SD Lim C Cohen JA Petros FF Marshall AS Neish, Am J Pathol 2001 158 1639 1651
39. Expression of CD9/motility-related protein 1 (MRP-1) in renal parenchymal neoplasms: consistent expression in papillary and chromophobe renal cell carcinomas. N Kuroda K Inoue L Guo E Miyazaki Y Hayashi K Naruse M Toi M Hiroi T Shuin H Enzan, Hum Pathol 2001 32 1071 1077
40. Lateral organization of membrane proteins: tetraspanins spin their web. S Charrin F le Naour O Silvie PE Milhiet C Boucheix E Rubinstein, Biochem J 2009 420 133 154
41. Tetraspan proteins: regulators of renal structure and function. MJ Caplan EJ Kamsteeg A Duffield, Curr Opin Nephrol Hypertens 2007 16 353 358
42. CD9 antigen mRNA is induced by hypertonicity in two renal epithelial cell lines. D Sheikh-Hamad JD Ferraris J Dragolovich HG Preuss MB Burg A Garcia-Perez, Am J Physiol 1996 270 253 258
43. A novel molecular staging protocol for non-small cell lung cancer. M Miyake M Adachi C Huang M Higashiyama K Kodama T Taki, Oncogene 1999 18 2397 2404
44. Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. M Higashiyama O Doi K Kodama H Yokouchi M Adachi CL Huang T Taki T Kasugai S Ishiguro S Nakamori M Miyake, Int J Cancer 1997 74 205 211
45. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. M Higashiyama T Taki Y Ieki M Adachi CL Huang T Koh K Kodama O Doi M Miyake, Cancer Res 1995 55 6040 6044
46. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. CI Huang N Kohno E Ogawa M Adachi T Taki M Miyake, Am J Pathol 1998 153 973 983 (Pubitemid 28419050)
47. Identification of molecular markers for metastasis-related genes in primary breast cancer cells. K Mimori A Kataoka K Yoshinaga M Ohta Y Sagara Y Yoshikawa S Ohno GF Barnard M Mori, Clin Exp Metastasis 2005 22 59 67
48. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. P Mhawech F Herrmann M Coassin L Guillou CE Iselin, Cancer 2003 98 1649 1657
49. Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Z Si P Hersey, Int J Cancer 1993 54 37 43
50. Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis. J Kusukawa F Ryu T Kameyama E Mekada, J Oral Pathol Med 2001 30 73 79
51. Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. CD Houle XY Ding JF Foley CA Afshari JC Barrett BJ Davis, Gynecol Oncol 2002 86 69 78
52. Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. G Sauer J Windisch C Kurzeder V Heilmann R Kreienberg H Deissler, Clin Cancer Res 2003 9 6426 6431
53. Tetraspanins: push and pull in suppressing and promoting metastasis. M Zoller, Nat Rev Cancer 2009 9 40 55
54. Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets. M Furuya H Kato N Nishimura I Ishiwata H Ikeda R Ito T Yoshiki H Ishikura, Cancer Res 2005 65 2617 2625
55. MRP-1/CD9 gene transduction downregulates Wnt signal pathways. CL Huang D Liu D Masuya K Kameyama T Nakashima H Yokomise M Ueno M Miyake, Oncogene 2004 23 7475 7483
56. MRP-1/CD9 gene transduction regulates the actin cytoskeleton through the downregulation of WAVE2. CL Huang M Ueno D Liu D Masuya J Nakano H Yokomise T Nakagawa M Miyake, Oncogene 2006 25 6480 6488
57. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. Y Murayama Y Shinomura K Oritani J Miyagawa H Yoshida M Nishida F Katsube M Shiraga T Miyazaki T Nakamoto, et al. J Cell Physiol 2008 216 135 143
58. The tetraspanin CD9 associates with transmembrane TGF-alpha and regulates TGF-alpha-induced EGF receptor activation and cell proliferation. W Shi H Fan L Shum R Derynck, J Cell Biol 2000 148 591 602
59. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. A Kunita TG Kashima Y Morishita M Fukayama Y Kato T Tsuruo N Fujita, Am J Pathol 2007 170 1337 1347
60. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Y Nakazawa S Sato M Naito Y Kato K Mishima H Arai T Tsuruo N Fujita, Blood 2008 112 1730 1739
61. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. T Nakamoto Y Murayama K Oritani C Boucheix E Rubinstein M Nishida F Katsube K Watabe S Kiso S Tsutsui, et al. J Gastroenterol 2009 44 9 889 96
62. Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: an automated tissue microarray study. W Huang K Kanehira S Drew T Pier, Appl Immunohistochem Mol Morphol 2009 17 12 17
63. Useful markers for differential diagnosis of oncocytoma, chromophobe renal cell carcinoma and conventional renal cell carcinoma. B Geramizadeh M Ravanshad M Rahsaz, Indian J Pathol Microbiol 2008 51 167 171
64. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. JP Higgins R Shinghal H Gill JH Reese M Terris RJ Cohen M Fero JR Pollack M van de Rijn JD Brooks, Am J Pathol 2003 162 925 932
65. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. MV Yusenko RP Kuiper T Boethe B Ljungberg AG van Kessel G Kovacs, BMC Cancer 2009 9 152